Accordingly, loss-of-function (LoF) variants are protective for cardiovascular disease,4 and less than 15 years after the discovery of this effect, therapeutic approaches to inhibit PCSK9 have been brought to market.5 Here, PCSK9 is linked to cardiovascular disorder.